Peripheral Artery Disease Treatment Denied by Insurance? How to Appeal

Peripheral artery disease (PAD) affects more than 8 million Americans and, when untreated, can progress from claudication to critical limb ischemia and amputation. Yet insurance companies routinely deny ankle-brachial index (ABI) testing, angioplasty, stenting, and revascularization procedures. In some tragic cases, patients lose limbs because insurance delays blocked timely intervention. If your PAD treatment has been denied, this guide explains your rights and how to fight back.

Common Denial Reasons for PAD Treatment

ABI testing denied — Ankle-brachial index testing is a non-invasive, inexpensive first step in PAD diagnosis. Insurers sometimes deny ABI studies by claiming they are included in a global evaluation or by miscoding them. Some plans require physician documentation of specific symptoms before approving vascular testing.

CT angiography or MR angiography denied — Before invasive intervention, vascular surgeons typically require imaging to map the arterial anatomy. Insurers may deny CTA or MRA as "not medically necessary" and insist on invasive angiography — or vice versa — creating a frustrating circular catch.

Angioplasty and stenting denied — Endovascular revascularization for claudication may be denied when the insurer argues that supervised exercise therapy (SET) has not been tried first. For critical limb ischemia, this argument should not apply, yet some insurers still apply it incorrectly.

Surgical bypass denied — Arterial bypass surgery (fem-pop bypass, tibial bypass) may be denied as "not medically necessary" when the insurer argues that endovascular options have not been exhausted, or that the patient's functional status doesn't justify the surgical risk.

"Amputation is equivalent" — In some of the most egregious cases, insurers have effectively denied revascularization while implying that amputation is an acceptable alternative. This is clinically and ethically indefensible and should be challenged aggressively.

Clinical Guidelines Supporting Your Appeal

AHA/ACC PAD Guideline (2024 update) — The ACC/AHA Guidelines for the Diagnosis and Management of Peripheral Artery Disease provide Class I recommendations for revascularization in patients with lifestyle-limiting claudication who have failed supervised exercise therapy, and for all patients with critical limb-threatening ischemia (CLTI). Document your Rutherford classification or Fontaine stage in your appeal.

Supervised Exercise Therapy (SET) — For claudication, CMS covers SET under a 2017 NCD when performed in a cardiac or vascular rehabilitation setting. SET is a Class I recommendation, but it does NOT apply to patients with CLTI (rest pain, ulcers, or gangrene). If your insurer is demanding SET before revascularization in a CLTI patient, cite the guidelines that explicitly exempt this population.

BEST-CLI and BASIL-2 Trials — These major trials compared open surgical revascularization to endovascular approaches in patients with CLTI. If your insurer is denying a specific revascularization approach, use the trial data to support the medical rationale for the chosen technique. Cite the trial results that show the approach your vascular surgeon recommends is appropriate.

WIfI Classification — The Wound, Ischemia, and foot Infection (WIfI) classification system quantifies limb threat in patients with CLTI and helps predict revascularization benefit. Submit your WIfI score in the appeal — it demonstrates the objective clinical basis for intervention.

Step-by-Step Appeal Strategy

Step 1: Classify your PAD severity. Denials for claudication are handled differently from denials for critical limb-threatening ischemia. Make absolutely clear in your appeal where you fall on the Rutherford or Fontaine scale, or submit your WIfI score. A patient with rest pain and a non-healing ulcer is in a different category than a patient with stable claudication.

Step 2: Document SET completion or contraindication. If you have completed supervised exercise therapy and have not improved sufficiently, submit those program records. If SET is contraindicated — due to rest pain, ulcers, severe cardiac comorbidity, or inability to exercise — document that explicitly and cite AHA/ACC guidance that excludes your situation from SET requirements.

Step 3: Submit vascular imaging and hemodynamic studies. ABI values, toe-brachial index (TBI), pulse volume recordings, and CT/MR angiography findings should all be included. These objective data points counter a "not medically necessary" denial with measurable hemodynamic impairment.

Step 4: Peer-to-peer with a vascular specialist. Request that your vascular surgeon conduct a peer-to-peer review with the insurer's medical reviewer. Insurers often assign generalist physicians as reviewers who lack vascular expertise — direct dialogue with a vascular surgeon frequently results in approval.

Step 5: Invoke limb-threatening urgency. If you have rest pain, non-healing wounds, or early gangrene, this is an urgent, potentially limb-threatening situation. File an expedited appeal and document the urgency explicitly. State law and ACA regulations require expedited decisions within 72 hours for urgent situations.

Step 6: File a complaint with your state insurance department. If the insurer is denying revascularization to a patient with critical limb ischemia, this may constitute bad faith or inappropriate application of utilization management criteria. State insurance commissioners take these complaints seriously.

Amputation vs. Revascularization: The Cost Argument

Ironically, revascularization is cost-effective compared to amputation when you account for prosthetics, rehabilitation, long-term disability, and reduced quality of life. Insurers who deny revascularization often incur greater total costs through downstream amputation-related care. Include this cost-effectiveness argument in your appeal if you believe the insurer is making a financially-driven rather than clinically-driven decision.

Published literature shows that major lower extremity amputation costs exceed $70,000 in the first year alone, with lifetime prosthetic and rehabilitation costs in the hundreds of thousands. Frame revascularization as the cost-effective, evidence-based alternative.

Fight Back With ClaimBack

Peripheral artery disease is progressive. Every month of delay increases your risk of amputation. ClaimBack helps you build a targeted, evidence-based appeal using your vascular studies, clinical classification, and the AHA/ACC guidelines that directly address your case.

Start your PAD appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied